Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14169479 | 0.87 | NOS1 (0.38) | NOS1NOS2CYP1A2 | |
| SCHEMBL11895228 | 0.82 | HLCS (0.30) | — | |
| SCHEMBL3327529 | 0.79 | — | — | |
| SCHEMBL8554107 | 0.75 | — | — | |
| SCHEMBL2690407 | 0.75 | CYP1A2 (0.47) | CYP1A2ALDH1A1EPHX1 | |
| SCHEMBL30931491 | 0.73 | CYP1A2 (0.50) | CYP1A2ALDH1A1EPHX1 | |
| SCHEMBL30931490 | 0.73 | CYP1A2 (0.50) | CYP1A2ALDH1A1EPHX1 | |
| SCHEMBL30518306 | 0.73 | CYP1A2 (0.50) | CYP1A2ALDH1A1EPHX1 | |
| SCHEMBL2692573 | 0.73 | CYP1A2 (0.50) | CYP1A2ALDH1A1EPHX1 | |
| SCHEMBL8025402 | 0.73 | CYP1A2 (0.50) | CYP1A2ALDH1A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797098-B1 | 3-OXA-10-AZA-PHENANTHRENES AS PDE4 OR PDE3/4 INHIBITORS | NYCOMED GMBH (DE) | 2011-05-04 | — | — | EP | disclosed |
| US-7838521-B2 | 3-oxa-10-aza-phenanthrenes | NYCOMED GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-20070259868-A1 | Novel 3-Oxa-10-Aza-Phenanthrenes | ALTANA PHARMA AG (DE) | 2007-11-08 | — | — | US | disclosed |
| EP-1797098-A2 | 3-OXA-10-AZA-PHENANTHRENES AS PDE4 OR PDE3/4 INHIBITORS | Altana Pharma AG (DE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006027344-A2 | 3-OXA-10-AZA-PHENANTHRENES AS PDE4 OR PDE3/4 INHIBITORS | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259868-A1 | Novel 3-Oxa-10-Aza-Phenanthrenes | PDE4A, PDE4B, PDE3A | NOS1 123/4885NOS2 209/4885CYP1A2 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.